INDEMNITY AGREEMENTIndemnity Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • New York
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [__], 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and _____________ (“Indemnitee”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • New York
This Investment Management Trust Agreement (this “Agreement”) is made as of [ ], 2020 by and between Eucrates Biomedical Acquisition Corporation (the “Company”) and Continental Stock Transfer & Trust Company (the “Trustee”).
Eucrates Biomedical Acquisition Corp. New York, New York 10019Securities Purchase Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • Virgin Islands
We are pleased to accept the offer you (the “Subscriber”) have made to purchase an aggregate of 2,875,000 ordinary shares (the “Shares”) of no par value per share (the “Ordinary Shares”), up to 375,000 of which Shares are subject to complete or partial forfeiture (the “forfeiture”) by you if the underwriters of the initial public offering (“IPO”) of Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”) do not fully exercise their over-allotment option (the “Over-allotment Option”). The terms on which the Company is willing to sell the Shares to the Subscriber, and the Company and the Subscriber’s agreements regarding such Shares, are as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of [__], 2020, by and among Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”), Eucrates LLC (the “Investor”) and any other holder of Registrable Securities (as defined below) which becomes a party to this Agreement pursuant to Section 6.2.
UNIT SUBSCRIPTION AGREEMENTUnit Subscription Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • Virgin Islands
This UNIT SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this [●] day of [●], 2020, by and between Eucrates Biomedical Acquisition Corp., a company incorporated in the British Virgin Islands with number 2042314 (the “Company”), having its principal place of business at 250 West 55th Street, Suite 13D, New York, New York 10019, and Eucrates LLC (the “Purchaser”).
WARRANT AGREEMENTWarrant Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • New York
This Warrant Agreement (this “Agreement”) made as of [_____], 2020 between Eucrates Biomedical Acquisition Corp., a British Virgin Islands company, with offices at 250 West 55th Street, New York, NY 10019 (“Company”), and Continental Stock Transfer& Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warrant Agent”).
UNITS CONSISTING OF ONE ORDINARY SHARE AND ONE-THIRD OF ONE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A COMMON STOCKUnit Certificate • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks
THIS CERTIFIES THAT _____________________________________________ is the owner of ______________________________________________________________ Units. Each Unit (“Unit”) consists of one (1) ordinary share, no par value per share, of EUCRATES ACQUISITION CORP., a British Virgin Islands company (the “Company”), and one-third (1/3) one (1) warrant (each whole warrant exercisable for one ordinary share) (a “Warrant”). Each whole Warrant entitles the holder to purchase one (1) ordinary share (subject to adjustment) for $11.50 per share (subject to adjustment). Only whole Warrants are exercisable. Each Warrant will become exercisable commencing on the later of (a) one year from the date of the final prospectus relating to the Company’s initial public offering (the “Final Prospectus”) and (b) thirty (30) days after the Company’s completion of an acquisition, share exchange, share reconstruction and amalgamation, contractual control arrangement or other similar business combination with one o
EUCRATES BIOMEDICAL ACQUISITION CORP. 10,000,000 Units Units, each consisting of one (1) ordinary share, no par value, and one-third of one warrant Underwriting AgreementUnderwriting Agreement • October 15th, 2020 • Eucrates Biomedical Acquisition Corp. • Blank checks • New York
